FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
JAMA Netw Open 2022 Jun 01;5(6)e2216199, A Klein-Brill, S Amar-Farkash, G Lawrence, EA Collisson, D AranFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.